Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1974 Mar;29(3):189–198. doi: 10.1038/bjc.1974.58

Development of Specific Cell-dependent Antibody During Growth of a Syngeneic Rat Sarcoma

C Basham, G A Currie
PMCID: PMC2009100  PMID: 4830142

Abstract

A micro-cytotoxicity assay was adapted for the detection of cell-dependent antibodies (CDA). Using normal rat spleens as the source of effector cells such CDA activity was readily demonstrable in allo-immune sera tested on cultured sarcoma cells. The same technique was then used to examine for tumour specific antibodies in the sera of Hooded rats bearing a “non-immunogenic” syngeneic metastasizing sarcoma. During the early stages of tumour growth, at Days 7 and 14, tumour specific CDA cytotoxicity was detectable at high titres. By Day 21, however, this activity had completely disappeared from the serum. This cell-dependent cytotoxicity was tumour specific in that it did not kill cells from an unrelated syngeneic sarcoma, and the activity was probably confined to immunoglobulin G as detected by molecular weight separation techniques. Following tumour amputation at Day 21, this type of specific antibody activity rapidly re-appeared in the serum. The presence of tumour specific CDA showed an inverse correlation with the presence of specific inhibitors of cell-mediated immunity in the same sera. At no stage in tumour growth could complement-dependent cytotoxicity be detected in tumour bearing rat sera.

It is concluded that cell-dependent cytotoxic activity is not associated with conventional complement dependence, that this CDA type of assay is exquisitely sensitive and is suitable for the detection of anti-TSTA antibodies in tumour bearing rats.

The possible significance of CDA activity in syngeneic tumour immunity is discussed briefly. The results suggest that the role of humoral immune mechanisms in host resistance to tumour growth needs re-appraisal.

Full text

PDF
189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Currie G. A., Alexander P. Spontaneous shedding of TSTA by viable sarcoma cells: its possible role in facilitating metastatic spread. Br J Cancer. 1974 Jan;29(1):72–75. doi: 10.1038/bjc.1974.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Currie G. A., Gage J. O. Influence of tumour growth on the evolution of cytotoxic lymphoid cells in rats bearing a spontaneously metastasizing syngeneic fibrosarcoma. Br J Cancer. 1973 Aug;28(2):136–146. doi: 10.1038/bjc.1973.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Currie G. A., Sime G. C. Syngeneic immune serum specifically inhibits the motility of tumour cells. Nat New Biol. 1973 Feb 28;241(113):284–285. doi: 10.1038/newbio241284a0. [DOI] [PubMed] [Google Scholar]
  4. Greenberg A. H., Hudson L., Shen L., Roitt I. M. Antibody-dependent cell-mediated cytotoxicity due to a "null" lymphoid cell. Nat New Biol. 1973 Mar 28;242(117):111–113. doi: 10.1038/newbio242111a0. [DOI] [PubMed] [Google Scholar]
  5. Hellström I., Hellström K. E., Warner G. A. Increase of lymphocyte-mediated tumor-cell destruction by certain patient sera. Int J Cancer. 1973 Sep 15;12(2):348–353. doi: 10.1002/ijc.2910120205. [DOI] [PubMed] [Google Scholar]
  6. Hersey P., Cullen P., MacLennan I. C. Lymphocyte-dependent cytotoxic antibody activity against human transplantation antigens. Transplantation. 1973 Jul;16(1):9–16. doi: 10.1097/00007890-197307000-00003. [DOI] [PubMed] [Google Scholar]
  7. Lamon E. W., Wigzell H., Andersson B., Klein E. Antitumour activity in vitro dependent on immune B lymphocytes. Nat New Biol. 1973 Aug 15;244(137):209–211. doi: 10.1038/newbio244209a0. [DOI] [PubMed] [Google Scholar]
  8. MacLennan I. C. Antibody in the induction and inhibition of lymphocyte cytotoxicity. Transplant Rev. 1972;13:67–90. doi: 10.1111/j.1600-065x.1972.tb00060.x. [DOI] [PubMed] [Google Scholar]
  9. Perlmann P., Perlmann H., Wigzell H. Lymphocyte mediated cytotoxicity in vitro. Induction and inhibition by humoral antibody and nature of effector cells. Transplant Rev. 1972;13:91–114. doi: 10.1111/j.1600-065x.1972.tb00061.x. [DOI] [PubMed] [Google Scholar]
  10. Pollack S., Heppner G., Brawn R. J., Nelson K. Specific killing of tumor cells in vitro in the presence of normal lymphoid cells and sera from hosts immune to the tumor antigens. Int J Cancer. 1972 Mar 15;9(2):316–323. doi: 10.1002/ijc.2910090209. [DOI] [PubMed] [Google Scholar]
  11. Pollack S. Specific "arming" of normal lymph-node cells by sera from tumor-bearing mice. Int J Cancer. 1973 Jan 15;11(1):138–142. doi: 10.1002/ijc.2910110116. [DOI] [PubMed] [Google Scholar]
  12. Proctor J. W., Rudenstam C. M., Alexander P. A factor preventing the development of lung metastases in rats with sarcomas. Nature. 1973 Mar 2;242(5392):29–31. doi: 10.1038/242029a0. [DOI] [PubMed] [Google Scholar]
  13. Thomson D. M., Steele K., Alexander P. The presence of tumour-specific membrane antigen in the serum of rats with chemically induced sarcomata. Br J Cancer. 1973 Jan;27(1):27–34. doi: 10.1038/bjc.1973.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Yust I., Wunderlich J. R., Mann D. L., Buell D. N. Cytotoxicity mediated by human lymphocyte-dependent antibody in a rapid assay with adherent target cells. J Immunol. 1973 Jun;110(6):1672–1681. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES